Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001362818 | SCV001558855 | likely benign | Short-rib thoracic dysplasia 10 with or without polydactyly; Retinitis pigmentosa 71 | 2024-10-22 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002504594 | SCV002815119 | uncertain significance | Short-rib thoracic dysplasia 10 with or without polydactyly; Retinitis pigmentosa 71; Bardet-Biedl syndrome 20 | 2024-01-23 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003132469 | SCV003813251 | uncertain significance | not provided | 2021-07-21 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003169814 | SCV003865127 | uncertain significance | Inborn genetic diseases | 2023-01-06 | criteria provided, single submitter | clinical testing | The c.3368A>G (p.N1123S) alteration is located in exon 30 (coding exon 30) of the IFT172 gene. This alteration results from a A to G substitution at nucleotide position 3368, causing the asparagine (N) at amino acid position 1123 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004738267 | SCV005357592 | uncertain significance | IFT172-related disorder | 2024-06-21 | no assertion criteria provided | clinical testing | The IFT172 c.3368A>G variant is predicted to result in the amino acid substitution p.Asn1123Ser. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.085% of alleles in individuals of South Asian descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |